GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Wolfgang P.

American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 ...

Both Indiana University and Memorial Sloan Kettering Cancer Center (MSKCC) have published their series’ of salvage high-dose ...

In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...

Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Joseph Allen discussing PSA response and survival based on metastatic site in patients with ...

Dr. Heidenreich notes that among the 86% of seminoma CSI patients, 15-30% relapse, of which 95% relapse in the retroperitoneum, nearly all relapses have good prognosis, and these patients are now CS ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...

GU ASCO annual meeting featured a kidney cancer session and a presentation by Dr. Michael Staehler discussing 18 F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell ...

Dr. Bergerot concluded her presentation discussing the development of FKSI-23, a new bespoke health-related quality of life questionnaire for the advanced and adjuvant setting in RCC with the ...

GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr.